Arachidonic Acid Metabolites: Mediators of Inflammation in Asthma
Author:
- 2 January 1997
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 17 (1P2) , 3S-12S
Abstract
Asthma is increasingly recognized as a mediator‐driven inflammatory process in the lungs. The leukotrienes (LTs) and prostaglandins (PGs), two families of proinflammatory mediators arising via arachidonic acid metabolism, have been implicated in the inflammatory cascade that occurs in asthmatic airways. The PG pathway normally maintains a balance in the airways; both PGD2 and thromboxane A2 are bronchoconstrictors, whereas PGE2 and prostacyclin are bronchoprotective. The actions of the LTs, however, appear to be exclusively proinflammatory in nature. The dihydroxy‐LT, LTB4, may play an important role in attracting neutrophils and eosinophils into the airways, whereas the sulfidopeptide leukotrienes (LTC4, LTD4, and LTE4) produce effects that are characteristic of asthma, such as potent bronchoconstriction, increased endothelial membrane permeability leading to airway edema, and enhanced secretion of thick, viscous mucus. Given the significant role of the inflammatory process in asthma, newer pharmacologic agents, such as the sulfidopeptide‐LT antagonists, zafirlukast, montelukast, and pranlukast and the 5‐lipoxygenase (5‐LO) inhibitor, zileuton, have been developed with the goal of targeting specific elements of the inflammatory cascade. These drugs appear to represent improvements to the existing therapeutic armamentarium. In addition, the results of clinical trials with these agents have helped to expand our understanding of the pathogenesis of asthma.Keywords
This publication has 34 references indexed in Scilit:
- Urinary leukotriene E4 in the assessment of nocturnal asthmaJournal of Allergy and Clinical Immunology, 1996
- Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.Thorax, 1993
- Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic AsthmaNew England Journal of Medicine, 1992
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991
- T Lymphocytes and Their Products in Atopic Allergy and AsthmaInternational Archives of Allergy and Immunology, 1991
- Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of asthmaScience, 1990
- Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic responseJournal of Allergy and Clinical Immunology, 1988
- Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects.Thorax, 1984
- Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and InflammationScience, 1983
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980